Addex Receives Additional $2.8 million from Indivior and Extends GABAB PAM Research Collaboration

Geneva, Switzerland, November 2, 2020 – Addex Therapeutics Ltd (SIX and Nasdaq: ADXN), a leading company pioneering allosteric modulation-based drug discovery and development, today announced that the research term of the agreement signed with Indivior PLC (LON: INDV) in January 2018 has been extended until June 30, 2021. The collaboration with Indivior covers the discovery of novel oral gamma-aminobutyric acid receptor subtype B (GABAB) positive allosteric modulator (PAM) compounds as potential therapies for multiple disease areas. As part of the amended agreement, Indivior has agreed to pay Addex $2.8 million in research funding and expand the therapeutic areas where Addex has exclusivity to develop retained compounds.

“The extension of our research collaboration and the additional funding from Indivior is a clear recognition of the potential of our allosteric modulator discovery platform and the significant achievements of our drug discovery team,” said Tim Dyer, CEO of Addex. “Indivior is a world leader in the development of addiction medication and strongly committed to GABAB PAM as a potential treatment for addiction including alcohol use disorder.”

“Although 200 health conditions have been linked to harmful alcohol use,1 there are few pharmacotherapies for alcohol use disorder (AUD) – their efficacy and uptake in clinical practice are limited, and patient acceptance is minimal. We are, therefore, very pleased to expand our partnership with Addex Therapeutics to discover and profile new potent and selective GABAB PAMs and provide a new class of medications that has the potential to achieve therapeutic benefits in patients suffering from AUD,” said Christian Heidbreder, Chief Scientific Officer of Indivior.

“Due to the extensive validation of GABAB activation with baclofen, we believe a novel, orally available GABAB PAM could provide significant benefits to patients in many therapeutics areas,” said Jean-Philippe Rocher, Co-Head of Discovery. “We have advanced multiple novel chemical series’ to late stages of lead optimization and we look forward to rapidly delivering first-in-class compounds for Indivior to advance into clinical development.”

Under the terms of the original agreement signed with Indivior in January 2018, Addex received a $5 million upfront payment and has since received $5.6 million research funding. Addex is eligible to receive up to $330 million of development, regulatory and commercialization milestones as well as tiered royalties up to teen double-digit. In addition, Addex has the right to retain certain compounds and pursue their development for reserved indications outside addiction, including for the treatment of Charcot-Marie-Tooth type 1a (CMT1A) neuropathy, a rare inherited disorder that affects peripheral nerves. Addex has discovered novel GABAB PAMs and has made significant progress in optimization of potential drug candidates. Addex expects to enter clinical candidate selection phase by end of 2020 and deliver drug candidates for IND enabling studies by the end of 2021 for both Indivior and for its in-house CMT1A program.

About GABAB Activation with PAM

Activation of the GABAB receptor, a Family C class of GPCR, is clinically and commercially validated by the generic GABAB

Read more

No New Deaths; 39 Additional Cases

ARLINGTON, VA —Virginia Department of Health confirmed 39 new cases Friday of COVID-19, the illness associated with the new coronavirus, in the Arlington Health District. That’s more than double the 17 reported on Thursday. The total number of COVID-19 cases in Arlington stands at 4,686.

Virginia health officials also reported no new deaths due to COVID-19 Friday in Arlington. The last new death was reported on Saturday. The total number of COVID-19-related deaths in the Arlington Health District now stands at 154.

A total of 541 people have been hospitalized in Arlington due to COVID-19.

VDH confirmed Thursday there have been 25 outbreaks of COVID-19 in the Arlington Health District. There have been 18 outbreaks at long-term care facilities, three at a congregate setting, three in health care settings, and, as of Tuesday, one at a college or a university. The total number of cases connected with an outbreak is 646. There have been 233 reported coronavirus cases in Arlington involving health care workers.

There have been 179,639 total cases statewide, according to data reported by the Virginia Department of Health. In Virginia, there have been 3,643 coronavirus-related deaths to date. There have been a total of 12,511 hospitalized COVID-19 patients.

VDH reported Monday that 83,792 COVID-19 tests have been taken in Arlington, with a 4.3 percent positivity rate. Statewide there have been 2,811,824 COVID-19 tests taken, with a 6.4 percent positivity rate, according to VDH.

Get the latest updates on the new coronavirus in Virginia as they happen. Sign up for free news alerts and a newsletter in your Patch town.

Globally, more than 45.1 million people have been infected by COVID-19, and over 1.1 million people have died, Johns Hopkins University reported Friday morning. In the United States, more than 8.9 million people have been infected and over 228,000 people have died from COVID-19.

VDH breaks down the number of cases and deaths in Arlington by age, race and ethnicity. The breakdown by age is as follows:

(VDH)
(VDH)

Arlington residents should take the following actions to help prevent the spread of COVID-19:

  • Avoid close contact with people who are sick.

  • Wash hands with soap and water for at least 20 seconds. An alcohol-based hand sanitizer can be used if soap and water are not available.

  • Avoid touching eyes, nose and mouth with unwashed hands.

  • Cover your cough or sneeze with a tissue, then throw the tissue in the trash.

  • Clean and disinfect frequently touched objects and surfaces.

Also see …

This article originally appeared on the Arlington Patch

Source Article

Read more

VitalHub Continues to Increase NHS UK Presence with Additional Regional Licensing Deal of Synopsis Products

TORONTO, Oct. 28, 2020 (GLOBE NEWSWIRE) — VitalHub Corp. (the “Company” or “VitalHub”) (TSXV: VHI) is pleased to announce the licensing of newly-acquired subsidiary Intouch With Health’s (“Intouch”) digital, at-home pre-op solutions, Synopsis iQ, to Northumbria Healthcare NHS Foundation Trust (“Northumbria” or the “Trust”).

Northumbria Healthcare NHS Foundation Trust has licensed VitalHub subsidiary Intouch’s digital pre-operative solution platform, Synopsis iQ, as the Trust launches a new digital pre-operative assessment (POA) pathway that will improve demand and capacity planning and resource utilization, helping to fill last-minute surgery slots and reducing the number of face-to-face appointments the department processes.

The Synopsis solution will enable Northumbria to meet a number of Trust targets, such as reducing the face-to-face appointments, which has become a much-needed requirement in the pandemic climate. Synopsis will provide the Trust with tools to afford patients with an improved experience leading up to surgery, affecting both the delivery and quality of care provided.

The project is part of the Trust’s drive to create a more efficient operating room booking pathway by creating a pool of ‘pre-op ready’ patients’ consultants can use to create operating room lists and fill last-minute surgery slots. As part of the project, patients waiting for surgery will also be able to complete their POA health questionnaire at home via a secure link on the Trust’s website. Results are then sent to the Trust’s pre-operative assessment department where staff can triage and swim-lane patients into the correct fitness and readiness categories.

The Trust identified a considerable burden on pre-op assessment departments, facing high volumes of last-minute requests for patient appointments, resulting in operating time delays and resource inefficiencies. Prior to the COVID-19 pandemic, the Trust established a target to reduce the number of face-to-face appointments patients had to attend, creating a need for a pre-op pathway solution, and has selected Synopsis iQ and Synopsis Home as their solutions of choice to enable the progression of this target.

Digitizing the pre-operative assessment process will also allow consultants and anaesthetists to access full patient notes from any of the Trust’s four hospital sites. The project will be rolled out across North Tyneside General Hospital, Northumbria Specialist Emergency Care Hospital, Hexham General Hospital and Wansbeck General Hospital, giving staff across all four hospitals secure access to patient records and a real-time view of each patient’s status through the pre-operative pathway.

Northumbria Healthcare NHS Foundation Trust is a regional healthcare network that provides a range of health and care services to support more than 500,000 people living in Northumberland and North Tyneside. The Trust delivers care from 11 sites, including their emergency care hospital, general and community hospitals, outpatient and diagnostic centers, an elderly care unit and an integrated health and social care facility. The Trust admitted over 116,000 patients and handled over 368,000 outpatient appointments in the 2017/18 period.

“We are seeing an aggressive uptick in awareness and interest in the Synopsis suite of products,” said Dan Matlow, CEO of VitalHub Corp. “With this contract, we add another

Read more

Upper Thumb sees 26 additional coronavirus cases Saturday

UPPER THUMB — Both Tuscola and Sanilac counties saw double-digit increases in confirmed coronavirus cases Saturday as the Upper Thumb reported 26 new confirmed cases.

Tuscola County, which has had significant increases multiple days over the past week, showed 11 new confirmed cases in the state report Saturday, bringing its total since the pandemic began to 558 cases. The state reports another 78 probable cases for the county. There were no additional deaths reported, with the toll remaining at 35.

Sanilac County also added 11 new confirmed cases Saturday, bringing its total to 170 since the pandemic began. The death tally remained at six with one additional probable death. Sanilac County also showed six probable cases.


Huron County had the smallest increase with four new confirmed cases Saturday, bringing its total since the pandemic began to 221. There were 43 more probable cases reported in Huron County, and the death toll remained at five Saturday.

Statewide, there were 3,338 new confirmed cases reported, the largest single-day number reported since the pandemic began. That brings the state’s total to 158,026 since the pandemic began. There were 35 deaths reported Saturday, and according to the state, 27 of those were identified during a vital records review.

Gov. Gretchen Whitmer tweeted Saturday, urging residents to use safety precautions to reduce the spread of the coronavirus.

“We are seeing an alarming rise in COVID-19 cases in Michigan right now,” Whitmer tweeted. “It is vital that we wear masks, avoid large gatherings, and practice social distancing.”

In the U.S., there were 82,929 new cases reported Saturday, bringing the national total to 8,469,976. There were 946 additional deaths across the country Saturday, bringing that total to 223,393.

Despite Michigan’s increase, the state remained 29th of all states and territories in cases reported in the last seven days. Michigan reported 18.6 cases per 100,000 people in the last seven days. North Dakota still led that category with 105.5 cases per 100,000 people. Wisconsin ranked fourth as its battle continued, with 62 cases per 100,000 people. Ohio ranked 30th, just behind Michigan, with 18.3 cases per 100,000 people, and Indiana ranked 18th with 30.4 cases per 100,000 people.

Source Article

Read more

No New Deaths; 12 Additional Cases

ARLINGTON, VA — Virginia Department of Health confirmed 12 new cases Monday of COVID-19, the illness associated with the new coronavirus, in the Arlington Health District. That’s down from the 29 reported on Sunday. The total number of COVID-19 cases in Arlington stands at 4,384.

Virginia health officials also reported no new deaths due to COVID-19 Monday in Arlington. On Saturday, VDH adjusted its numbers for Arlington, removing one death from it running total. The total number of COVID-19-related deaths in the Arlington Health District now stands at 152.

A total of 519 people have been hospitalized in Arlington due to COVID-19.

VDH confirmed 20 outbreaks of COVID-19 at long-term care facilities in the Arlington Health District. There have been two outbreaks at a congregate setting and three outbreaks in health care settings. The total number of cases connected with an outbreak stands at 589. There have been 224 reported coronavirus cases in Arlington involving health care workers.

There have been 166,828 total cases statewide, according to data reported by the Virginia Department of Health. In Virginia, there have been 3,457 coronavirus-related deaths to date. There have been a total of 11,882 hospitalized COVID-19 patients.

VDH reported Monday that 76,887 COVID-19 tests have been taken in Arlington, with a 3.8 percent positivity rate. Statewide there have been 2,583,644 COVID-19 tests taken, with a 5.6 percent positivity rate, according to VDH.

Get the latest updates on the new coronavirus in Virginia as they happen. Sign up for free news alerts and a newsletter in your Patch town.

Globally, more than 40.1 million people have been infected by COVID-19, and over 1.1 million people have died, Johns Hopkins University reported Monday morning. In the United States, more than 8.1 million people have been infected and over 219,000 people have died from COVID-19.

VDH breaks down the number of cases and deaths in Arlington by age, race and ethnicity. The breakdown by age is as follows:

(VDH)
(VDH)

Arlington residents should take the following actions to help prevent the spread of COVID-19:

  • Avoid close contact with people who are sick.

  • Wash hands with soap and water for at least 20 seconds. An alcohol-based hand sanitizer can be used if soap and water are not available.

  • Avoid touching eyes, nose and mouth with unwashed hands.

  • Cover your cough or sneeze with a tissue, then throw the tissue in the trash.

  • Clean and disinfect frequently touched objects and surfaces.

Also see …

This article originally appeared on the Arlington Patch

Source Article

Read more

COVID-19 Related Breast Cancer Surgery Delays Could Result in Nearly 3,000 Additional Deaths Over a 10 Year Period

Delays in treatment also place patients at higher risk of metastasis, increasing cost of care by more than $375 million during that time

Delays in breast cancer surgery due to the COVID-19 pandemic could lead to an additional 2,797 deaths over the next decade according to Kantar Health, a leading global healthcare data, analytics and research provider, Delays in treatments could result in an additional $376 million in treatment costs over that time period due to more patients developing metastasis. The analysis, released as part of World Breast Cancer Awareness Month, is based on Kantar Health’s CancerMPact® Patient Metrics database, a decision support resource for oncology market analysis, strategic planning and identifying commercial opportunities.

Research from the American Association of Cancer Research found that 32% of those who were diagnosed with breast cancer reported a delay in care. Of these patients, 22% reported a delay in screening and 9.3% reported a delay in treatment.

Kantar Health’s CancerMPact Patient Metrics database1 estimates the incidence of breast cancer in the United States in 2020 to be 335,779. Of those, 319,700 patients will be diagnosed with non-metastatic disease. If these patients with non-metastatic disease receive appropriate and timely care, they have good potential for a positive outcome. However, delays in care, especially surgery, compromises this. For breast cancer, a delay in surgery of 60 days is estimated to cause an increase in the number of deaths of 4% and 7% at five and ten years post-diagnosis respectively2.

Based on Kantar Health’s estimates of the total annual number of new cancer patients, it is expected that the number of patients diagnosed with non-metastatic during the first three months of the pandemic totaled 79,925 patients.

Of these patients, Kantar Health forecasts that deaths among breast cancer patients could increase by 1,598 deaths five years post-diagnosis and 2,797 deaths ten years post-diagnosis.

Further, Kantar Health expects an excess in the overall costs of cancer treatment due to COVID-19, as a proportion of patients will develop metastasis over the course of their disease. In the five years post-COVID-19, additional costs will total $215.2 million for breast cancer patients. In ten years, this number could almost double, to $376.7 million for breast cancer care.

“The effects of the pandemic will be felt deeply in many disease areas, but none more so than in oncology,” said Jeremy Brody, Chief Strategy Officer, Kantar Health. “It is important that patients continue to maintain their regular appointments and screenings to detect and treat breast cancer. The COVID-19 global pandemic needs to be a catalyst for the healthcare system to seek new ways to reach patients and ensure early detection screenings continue.”

Refs

  1. CancerMPact Patient Metrics Database [Internet]. Kantar Health. 2020 [cited May, 2020]. Available from: www.cancermpact.com.

  2. Bleicher RJ, Ruth K, Sigurdson ER, Beck JR, Ross E, Wong YN, et al. Time to Surgery and Breast Cancer Survival in the United States. JAMA oncology. 2016;2(3):330-9.

About Kantar Health

Kantar Health, a division of Kantar, provides data, analytics and

Read more